The Flexi-Cap features a first-opening indication as an anticounterfeiting solution.
Schreiner MediPharm's Flexi-Cap label-and-cap combination features a first-opening indication that prevents the illegal reuse of medicine containers under the guise of being unopened, original products. Flexi-Cap comprises a label combined with a cap that gives a clear and irreversible indication that a primary container has been opened. The technology is similar to the cover for wine bottles but adapted to the specific requirements of the pharmaceutical industry.
To use Flexi-Cap, the film cap is positioned over the closed container, and the label is applied without covering the peel-open tab of the opening strip. Once the strip is opened, the bottom part of the cap, together with the label, remains attached to the container. Attempting to remove the rest of the cap destroys the label, thus eliminating the possibility of unnoticed illegal reuse.
Flexi-Cap enables flexible use with different container types, forms, and sizes. In contrast to shrink-wrap solutions, the label construction can be applied without using heat, making the solution viable for temperature-sensitive medicines. The pharmaceutical manufacturer's label and brand design remain unchanged, due to the combination of label and cap. In addition, the top of the cap allows space for bar code printing or chip integration for electronic tracking.
Source: Schreiner MediPharm
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.